These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 21276949)

  • 1. 17-hydroxyprogesterone caproate, progesterone, preterm birth prevention, and safety: who decides? Someone should.
    O'Brien JM
    Am J Obstet Gynecol; 2011 May; 204(5):e16-7; author reply e17. PubMed ID: 21276949
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
    O'Brien JM; Lewis DF
    Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
    Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?
    Manuck TA
    Semin Perinatol; 2017 Dec; 41(8):461-467. PubMed ID: 28947068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?
    Hall NR
    Obstet Gynecol Clin North Am; 2011 Jun; 38(2):235-46, ix-x. PubMed ID: 21575799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is 17α-hydroxyprogesterone caproate contraindicated in twin gestations?
    Romero R; Conde-Agudelo A
    BJOG; 2015 Jan; 122(1):6-7. PubMed ID: 25280114
    [No Abstract]   [Full Text] [Related]  

  • 7. 17-alpha-hydroxyprogesterone caproate versus vaginal progesterone suppository for the prevention of preterm birth in women with a sonographically short cervix: A randomized controlled trial.
    Pirjani R; Heidari R; Rahimi-Foroushani A; Bayesh S; Esmailzadeh A
    J Obstet Gynaecol Res; 2017 Jan; 43(1):57-64. PubMed ID: 27775195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice.
    Romero R; Stanczyk FZ
    Am J Obstet Gynecol; 2013 Jun; 208(6):421-6. PubMed ID: 23643669
    [No Abstract]   [Full Text] [Related]  

  • 9. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
    Odibo AO; Stamilio DM; Macones GA; Polsky D
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth.
    Hines M; Lyseng-Williamson KA; Deeks ED
    Clin Drug Investig; 2013 Mar; 33(3):223-7. PubMed ID: 23413110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 17-α hydroxyprogesterone caproate for the prevention of preterm birth.
    Gupta S; Roman AS
    Womens Health (Lond); 2012 Jan; 8(1):21-30. PubMed ID: 22171770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 17-Hydroxyprogesterone caproate (17OHP-C) coverage among eligible women delivering at 2 North Carolina hospitals in 2012 and 2013: A retrospective cohort study.
    Stringer EM; Vladutiu CJ; Manuck T; Verbiest S; Ollendorff A; Stringer JS; Menard MK
    Am J Obstet Gynecol; 2016 Jul; 215(1):105.e1-105.e12. PubMed ID: 26829508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal routes of administration, vehicles and timing of progesterone treatment for inhibition of delivery during pregnancy.
    Fang D; Moreno M; Garfield RE; Kuon R; Xia H
    Eur J Obstet Gynecol Reprod Biol; 2017 Sep; 216():164-168. PubMed ID: 28777967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery.
    Saghafi N; Khadem N; Mohajeri T; Shakeri MT
    J Obstet Gynaecol Res; 2011 Oct; 37(10):1342-5. PubMed ID: 21564406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
    O'Brien JM
    Obstet Gynecol; 2012 Feb; 119(2 Pt 1):384-5; author reply 385-6. PubMed ID: 22270303
    [No Abstract]   [Full Text] [Related]  

  • 16. 17 Alpha-hydroxyprogesterone caproate for preterm prevention: issues in subgroup analysis.
    Klebanoff MA
    Am J Obstet Gynecol; 2016 Mar; 214(3):306-7. PubMed ID: 26928145
    [No Abstract]   [Full Text] [Related]  

  • 17. 17α Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Merlob P; Stahl B; Klinger G
    Reprod Toxicol; 2012 Jan; 33(1):15-9. PubMed ID: 22120850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Progesterone Utilization and Birth Outcomes in a State Medicaid Plan.
    Hydery T; Price MK; Greenwood BC; Takeshita M; Kunte PS; Mauro RP; Lenz K; Jeffrey PL
    Pharmacotherapy; 2017 Oct; 37(10):1328-1334. PubMed ID: 28833362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rebirth of progesterone in the prevention of preterm labor.
    Schmouder VM; Prescott GM; Franco A; Fan-Havard P
    Ann Pharmacother; 2013 Apr; 47(4):527-36. PubMed ID: 23535817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate.
    Bailit JL; Votruba ME
    Am J Obstet Gynecol; 2007 Mar; 196(3):219.e1-7. PubMed ID: 17346527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.